Home › NDC Lookup › RxCUI directory › RxCUI 2274390

Tazemetostat 200 MG Oral Tablet [Tazverik] — RxCUI 2274390

RxNorm drug concept · Semantic branded drug
RxCUI 2274390 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2274390
Official nameTazemetostat 200 MG Oral Tablet [Tazverik]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asTazverik 200 MG Oral Tablet; Tazverik 200 MG (equivalent to 228 MG tazemetostat HBr) Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)97 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tazemetostat: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Tazverik is used to treat two types of cancer. First, it's approved for people 16 and older with a rare soft-tissue cancer called epithelioid sarcoma when surgery can't completely...
  • You take Tazverik tablets by mouth twice a day — and the good news is you can take them with or without food, so a heavy meal won't throw off how the medicine works. Swallow the ta...
  • How do I take Tazverik, and does it matter if I take it with food?
  • The most common side effects include fatigue, nausea, pain, decreased appetite, vomiting, and constipation — or, if you're being treated for follicular lymphoma, you might also not...
📖 Read our full Tazemetostat guide →

🕸️ Concept Web — How Tazemetostat 200 MG Oral Tablet [Tazverik] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tazemetostat 200 MG Oral Tablet [Tazverik] RxCUI 2274390

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tazemetostat 2274378
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tazverik 2274385
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tazemetostat Oral Tablet 2274383
    • Tazemetostat Oral Product 2274381
    • Tazemetostat Pill 2274382
    • Tazemetostat Oral Tablet [Tazverik] 2274387
    • Tazverik Oral Product 2274388
    • Tazverik Pill 2274389
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tazemetostat 200 MG Oral Tablet SCD · 2274384
  • Tazemetostat 200 MG SCDC · 2274380
  • Tazemetostat Oral Tablet SCDF · 2274383
  • Tazemetostat Oral Product SCDG · 2274381
  • Tazemetostat Pill SCDG · 2274382

Brand-Name Concepts

  • Tazemetostat 200 MG [Tazverik] SBDC · 2274386
  • Tazemetostat Oral Tablet [Tazverik] SBDF · 2274387
  • Tazverik Oral Product SBDG · 2274388
  • Tazverik Pill SBDG · 2274389
  • Tazverik BN · 2274385

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2274390 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
72607-0100-00 240 TABLET, FILM COATED in 1 BOTTLE (72607-100-00) TAZVERIK Epizyme, Inc. 2020-01-23
Observed labelers: Epizyme, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.